Background: Prescription patterns for acne/rosacea medications have not been described in the Medicare population, and comparisons across specialties are lacking.
A bout 65%-72% of medical appointments scheduled for the treatment of rosacea are with dermatologists, and the remaining are with by family physicians, internists, and ophthalmologists. 1, 2 Only 15% of patients with acne are seen by specialties other than dermatologists. 3 The cost of acne and rosacea prescription medications in the United States totaled $2 billion in 2004, 4 suggesting that prescription choices for these diseases have a large impact on national health care expenditure. Previous studies examined prescription patterns 1, [5] [6] [7] and costs [8] [9] [10] [11] in acne and rosacea in populations primarily \65 years of age. Further, comparisons of prescription costs across different specialties are lacking. A recent investigation showed that in comparison to primary care physicians, specialists prescribed more brand-name drugs and a broader range of topical steroids, which was a practice associated with increased costs. 12 We hypothesized that similar prescribing patterns occur for acne/rosacea treatments. Understanding the patterns and costs of prescription medications might offer insight into strategies to reduce health care costs. In this study, we analyzed total and out-of-pocket costs and prescribing patterns of acne/rosacea treatments across different specialties in the Medicare population.
METHODS

Data source and variables
As described previously, 12 a cross-sectional study was performed of the 2008 and 2010 Prescription Drug Profiles Public Use Files released by the Centers for Medicare and Medicaid Services, 13 representing 100% of Medicare part D prescription drug claims. Data are reported as profilesdaggregates of prescriptions with the same categorical variable values with continuous variables reported as a mean. For example, a profile can represent 20 claims, all for the same drug, patient sex, age group, insurance plan type, and prescriber type. Topical retinoids, topical antibiotics indicated for acne/rosacea, $30-day courses of oral tetracycline-class-antibiotics (TCA), and oral isotretinoin were selected for this analysis. Specific drugs selected and other variables reported in the data set are presented in Supplemental Table I (available at http://www.jaad.org).
Prescriber taxonomy
Prescriber specialty was reported as 1 of the 6 categories. They included family medicine (FM), internal medicine (IM), psychiatry/neurology, specialist, other, and suppressed (to protect patient confidentiality; algorithm detailed in Supplemental Table I ; available at http://www.jaad.org). We merged the specialist and other categories of the prescription drug profiles into a single specialist category with the assumption that most were dermatologists. This assumption was validated against prescriber distributions from the 2014 Medicare Provider Utilization and Payment Data, 12,14 which includes dermatology as a specific specialty (Supplemental Table II ; available at http:// www.jaad.org). Suppressed prescribers were considered in a separate category to avoid potential biases from the suppression algorithm. The final provider designations compared in the analyses were FM, IM, specialist, and suppressed.
Statistical analysis
Statistical analyses, as described previously, 12 were performed in MATLAB (version R2015b, MathWorks, Natick, MA). Primary outcomes examined were total cost (the sum of costs paid for ingredients, dispensing fee, and sales tax) and patient cost (nonreimbursed cost paid by the beneficiary) of prescriptions. Costs per prescription were normalized to a length of 30 days. The 2008 costs were adjusted for inflation to 2010 prices using the Consumer Price Index from the US Bureau of Labor Statistics. 15 Summary statistics were calculated for yearly aggregate cost, mean cost per prescription, and mean prescription length of each drug. Mean drug costs are presented for both generic and branded versions for comparison. Prescription frequencies and brand name usage were calculated and stratified by provider type.
Multivariable linear regression was used to model log-transformed costs in each drug class against prescriber specialty and covariates. This model was designed to reflect the effects of specialty-dependent differences in medication and brand choice on costs of treatments with similar efficacy and indications. Linear modeling produced residuals with positive skew, so costs were log-transformed. Total cost was modeled against specialty with covariates of sex, age, year, and prescription drug hierarchical conditional category (risk score that reflects health status phase, benefit structure, gap coverage, year, and prescription drug hierarchical conditional category.
RESULTS
All-provider costs and patterns
The total cost of all acne/rosacea medications was $65.2 million in 2008 and $73.5 million in 2010 (Table I ). The distribution of prescriptions in both years was 12%-13% (or $11-$12 million total aggregate costs) for topical retinoids, 63% (or $44-$48 million total aggregate costs) for topical antibiotics, 24%-25% (or $9-$12 million total aggregate costs) for TCA, and 0.4%-0.5% (or $1.3-$2.1 million total aggregate costs) for isotretinoin. Women received 58% and patients $65 years received 71% of prescriptions. Topical antibiotics was the most commonly prescribed class of drug prescribed for all sexes and age groups. Men and patients $65 years utilized more TCAs and less topical retinoids than women and patients \65 (Fig 1) .
Tretinoin was the lowest cost and most commonly prescribed topical retinoid, accounting for 78% of prescriptions in 2008 and 84% in 2010. About 14%-17% of tretinoin prescriptions were brand name, which cost more than generics per 30-day prescription (total cost $115-$138 vs $65-$72; patient cost $28-$37 vs $8-$10).
The most common topical antibiotics prescribed were metronidazole (50% in 2008 and 2010) and clindamycin (26% in 2008 and 29% in 2010). Fortytwo percent of topical metronidazole prescriptions in 2008 were brand name. Brand name metronidazole had a higher mean total cost ($163) and patient cost ($43) than the generic version ($86 and $10, respectively). Branded metronidazole usage decreased to 28% in 2010. Branded clindamycin was less frequently prescribed (2%-5%), but much more expensive than generic (total cost $239-$289 vs $35-$38; patient cost $44-$49 vs $5).
Of TCA prescriptions, 48%-49% were tetracycline, 41%-42% were minocycline, and 10% were doxycycline. Less than 2% of tetracycline and minocycline prescriptions were brand name, but 62%-63% of doxycycline prescriptions were branded, resulting in higher total ($191-$334 vs $32-$33) and patient ($51-$82 vs $8-$10) costs.
From 2008 to 2010, all generic medications saw decreases or nominal (\$3) increases in total and patient cost. Many brand name drugs, however, increased in cost. The mean total cost increased by 26%-31% for branded adapalene, tazarotene, metronidazole, and minocycline; 43% for isotretinoin; and 74% for branded doxycycline. Mean patient costs for brand names increased by 18%-19% for adapalene and tazarotene, 56% for combined clindamycin/ tretinoin, 32%-35% for metronidazole and sulfacetamide, 61%-63% for doxycycline and minocycline, and 25% for isotretinoin. Brand name prescribing in 2010 decreased for all drugs except topical erythromycin (which increased from 4% to 11%) and sulfacetamide/sulfur (which increased from 41% to 49%).
Specialty differences
Prescription distributions and brand name prescription stratified by provider specialty are presented in Table II . Specialists prescribed a higher percentage of brand names than FM and IM physicians for every medication except adapalene. IM physicians generally prescribed brand names more often than FM physicians. The most notable differences between specialties were for sulfacetamide/ sulfur (36% brand name usage by specialists vs \1% usage by FM/IM physicians) and doxycycline (60% by specialists, 56% by IM physicians, and 27% by FM physicians). Topical tretinoin and metronidazole, the most commonly prescribed drugs in their respective classes, were also prescribed more often by brand name by specialists than by brand name by FM/IM physicians (14% vs 8%-11% for tretinoin; 35% vs 29%-32% for metronidazole).
Non-tretinoin topical retinoids were prescribed more often by specialists (16%) than by FM/IM physicians (7%-9%). For topical antibiotics, specialists prescribed metronidazole less often (49% vs 56%-61%) and azelaic acid more often (8% vs 1%) than FM/IM physicians did. For TCA, doxycycline was prescribed more frequently by specialists (16%) than by FM/IM physicians (\1%). Specialists prescribed topical retinoids more often (14%) than FM/IM physicians did (7%-8%), and FM/IM physicians prescribed TCAs more often (32%-33%) than specialists did (23%).
Multivariable linear regression was used to model mean log-transformed total and patient costs per 30-day prescription against prescriber specialty and covariates (Table III) . Specialist prescriptions for topical retinoids were associated with total costs $18-$20 higher and patient costs $2-$3 higher than the corresponding prescriptions from FM/IM physicians. Patient costs for topical antibiotics from specialists were $1 higher than they were from FM/ IM physicians, but differences in total cost ($1-$2) between specialties were not statistically significant. The cost of TCAs prescribed by specialists were higher than those prescribed by FM physicians (total and patient costs were $18 and $4 higher, respectively). Also, the costs for TCAs prescribed by IM physicians were higher than those prescribed by FM physicians (total and patient costs were $3 and $1 higher, respectively).
DISCUSSION
This study found significant differences in the costs between specialist and FM/IM physicians prescriptions for acne/rosacea medications. Total costs for topical retinoids and TCA prescriptions were highest when written by specialists, and amounted to $3-$4 million per year more than FM/IM prescriptions from the same drug classes or 5%-6% of all Medicare acne/rosacea prescription costs. Given that acne/rosacea are very common in patients \65 years of age, this represents an opportunity for large savings in health care expenditures. The higher costs associated with specialist prescriptions are also seen by patients, with mean out-of-pocket cost differences ranging 14%-70% more for each drug prescribed by a specialist.
The differences in cost between specialties can be attributed to differences in prescription patterns. Specialists prescribed a higher percentage of brand names for all drugs but adapalene, and the differences were often larged6%-7% higher than FM physicians for common medications such as topical tretinoin, metronidazole, and benzoyl peroxide. Specialists also prescribed a broader range of medications, prescribing more expensive options such as tazarotene, azelaic acid, and sulfacetamide more often than FM/IM physicians.
There are numerous reasons for differences in prescription patterns across specialties. Specialists are expected to see more patients with complex medical histories who might have failed less expensive or generic options. Specialists are also astute to subtle differences between medications of the same class, such as drug interactions, vehicle preference, and side effects. Patient preference and compliance is also an important consideration that could influence medication choice. Although patients might be willing to pay more for a complete versus a partial clearance of acne, 16 the doctor's choice of prescribing branded drugs is also subject to external influences, such as interactions with pharmaceutical sales representatives, 17 direct-toconsumer advertising, 18 and provision of free samples. 19 The former 2 influences might lead to the specialist to choosing a drug based on tolerability and aesthetics of the vehicle without regard to their comparative effectiveness. Branded topical metronidazole was more than twice the total cost and 5 times the patient cost of generic versions, yet brand name usage was high across all specialties despite similar efficacy of branded gel in comparison with cream and lotion vehicles. 20 A limitation of this study was that prescriptions in the data set were not accompanied by a diagnosis. Therefore, some of the prescriptions analyzed, particularly the TCAs, could have been written for conditions other than acne/rosacea. To limit the number of prescriptions for infections, we only included prescription profiles with a mean duration $30 days, as guidelines for skin and soft tissue infections recommend oral antibiotics for no longer than 7-14 days. 21 Another limitation of the data set was the grouping of prescriptions into profiles and data suppression. The 30-day duration threshold used on TCA is likely to exclude some acne/rosacea prescriptions that are grouped with shorter ones that bring the mean length of the profile to \30 days. We believe the largest impact was on doxycycline because it is the most common TCA for infections.
To protect confidentiality of beneficiaries, certain variables, including prescriber specialty, were suppressed if #10 patients shared the same values for all categorical variables. Uncommon prescriptionsd usually also more expensivedare likelier to be suppressed, which is reflected by suppressed prescribers being associated with the highest total costs. Because less common medications are more often prescribed by specialists, the true costs associated with specialists are probably higher than those presented; the true cost potentially lies somewhere between specialist cost and suppressed cost. In addition, lack of an explicit prescriber category for dermatology is a limitation. By validation with an external data set, we found that 80%-86% of topical retinoids, 63%-100% for topical antibiotics, and 48%-65% for TCA for $30-day prescriptions were from specialists who were actually dermatologists. These percentages would be even higher if including midlevel providers, who might be employed in dermatology practices but are categorized separately. Other specialist prescribers of TCA included ophthalmologists and dentists. Thus, the specialist category is largely representative of dermatologists, especially for topical retinoid and antibiotic prescriptions. Lastly, prescription costs and practices have likely changed in the past 7-9 years since this data was collected. A comparison with the 2017 National Average Drug Acquisition Cost 22 shows similar current costs of generic topical retinoids (tretinoin the lowest, followed by adapalene) and topical antibiotics (benzoyl peroxide is now the lowest, followed by clindamycin, erythromycin, and metronidazole). The most notable change is a substantial increase in the cost of tetracycline, while generic doxycycline and minocycline are slightly lower than they were in 2010. Brand name costs have increased for most medications since 2010. It is possible that practice patterns and formulary restrictions have changed as well, so further studies are needed to evaluate their impact on specialty-dependent prescription costs once new data is available.
In conclusion, we describe prescription patterns for acne/rosacea in the Medicare population. The most common drug class used was topical antibiotics, accounting for 63% of all prescriptions. Specialist prescriptions were associated with higher total and patient costs than FM/IM prescriptions for all drug classes except topical antibiotics (which was associated with higher patient but not total costs). Treatment costs could be reduced by prescribing more generics and less expensive options within the same drug classes. Use of higher-cost dermatology drugs should be backed by evidence of improved outcomes. Further research is needed to determine the comparative efficacy of different acne/rosacea treatments. 
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